The prevalence of phenotypic drug resistance was assessed in 60 patients with a viral rebound after they received a protease inhibitor (PI)-or nonnucleoside reverse transcriptase inhibitor (NNRTI)-containing regimen (baseline). Resistance testing was done within 36 weeks of viral rebound; no resistance testing was available at baseline. All patients had previously received zidovudine; 86.0% had received lamivudine. In total, 45.1% of the patients had strains resistant to the PI that they started and 88.9% given nevirapine had strains with reduced susceptibility to that drug. Overall, 46 patients (76.7%) harbored a strain resistant to у1 drug of their initial PI-or NNRTI-containing regimen. Of 53 patients who remained on treatment at the time of the study (40 had switched to a different combination from that at baseline), 6 harbored isolates susceptible to all drugs they had ever received. Thus, patients with viral rebound while on potent antiretroviral therapy usually have reduced susceptibility to у1 drug. Viral rebound also occurs in persons in whom resistant strains could not be detected by the assay used.
Potent combination therapy containing protease inhibitors (PI) or nonnucleoside reverse transcriptase inhibitors (NNRTI) plus 2 nucleoside analogues has dramatically changed the natural history of human immunodeficiency virus (HIV) disease [1] . However, recent studies have shown that a significant number of patients eventually experience a virologic failure to these drug combinations, which can be partly explained by the development of resistance [2, 3] . Moreover, several recent reports show that HIV resistance is strongly predictive of virologic failure in drug-experienced patients. Deeks et al. [4] reported a significant correlation between phenotypic drug susceptibility and virologic outcome in 18 patients who had a viral rebound while on indinavir-containing regimens. Montaner et al. [5] found that resistance to prescribed drugs and drug classes predict lack of virologic response in heavily pretreated patients. Similarly, there was a correlation between phenotype of plasma HIV variants and virologic response in a study of pretreated patients in whom у1 PI failed [6] . In most of these small studies, phenotypic resistance was a more important predictor of virologic failure than CD4 cell count, virus load, or previous drug history; however, rebounds in virus load have also been observed in patients with wild type virus [3, 7, 8] .
The aim of this study was to calculate the prevalence of resistance in patients from the Frankfurt HIV clinic cohort. HIV drug resistance was determined after virus load rebound following initiation of therapy with a PI or NNRTI. We focused on the proportion of patients who had resistant isolates to у1 drug that was in their initial PI-or NNRTI-containing regimen.
Methods
Patients. We studied a group of patients enrolled in the Frankfurt HIV clinic cohort who started a PI or NNRTI and (1) whose virus load either decreased to !500 copies/mL and subsequently increased to 1500 copies/mL or (2) decreased by у1.0 log 10 copies/ mL and subsequently increased by у0.5 log 10 copies/mL above this initial reduction. We defined the initial PI or NNRTI regimen as the "baseline regimen," even though most patients previously had received nucleoside analogues. Patients were included in the analysis only if they had a phenotypic assay test complete for all drugs included in the baseline regimen within 36 weeks of the date of viral rebound. The date of viral rebound was defined as the first time virus load was 1500 copies/mL or the first time an increase у0.5 log 10 copies/mL occurred. Prevalence of resistance was calculated separately in groups 1 and 2, and the analysis was repeated using only patients still receiving antiretroviral treatment at the time of the phenotypic resistance test. In these patients, in addition to the drugs of the baseline regimen, we calculated the prevalence of isolates resistant to any of the drugs received prior to the test that subjects were receiving at the date of resistance testing. Virus load was measured about every 4 weeks by quantitative reverse transcription polymerase chain reaction (Amplicor; Roche Molecular Systems, Nutley, NJ) with a minimum quantifiable level of 500 copies/mL. Since January 1998, we have used the ultrasensitive assay (with lower quantification limit of 50 copies/mL) for virus load !500 copies/mL.
Resistance testing. Phenotypic resistance to all currently available antiviral agents was assessed by use of a recombinant virus assay (Antivirogram; Virco Laboratories, Mechelen, Belgium) [9] . An isolate was considered resistant to a drug if the IC 50 was at least 4-fold higher than the IC 50 for the wild type control virus.
Results
The study population comprised 598 patients in the Frankfurt HIV clinic cohort: 467 (78.1%) who started a PI or a NNRTI, whose virus load decreased to !500 copies/mL upon initiation of therapy and subsequently increased to 1500 copies/ mL and 131 patients (21.9%) who also started a PI or a NNRTI, whose virus load remained 1500 copies/mL but who experienced an initial drop of у1.0 log 10 copies/mL RNA and a subsequent viral rebound of у0.5 log 10 .
Phenotypic resistance for у1 PI or NNRTI was tested within 36 weeks after the estimated date of viral rebound in 60 patients (median, 19 weeks; range, 1-35 weeks). In total, 33 patients (7.1% of the total study population) were in group 1 and 27 (20.6% of the total study population) in group 2. Details of the characteristics of these patients at the time they began the baseline regimen are shown in table 1. The majority (53.3%) started indinavir, and 15% started an NNRTI (nevirapine in all cases). Stavudine and lamivudine were the most frequent nucleosides started at the same time. Ten patients (16.7%) were antiretrovirally naive at baseline; of the antiretroviral-experienced patients, all had received zidovudine and most (86.0%) had received lamivudine.
The frequency of resistance after viral rebound is given in table 2. Eighteen patients (30.0%) had virus strains that were resistant to only 1 of the drugs in the baseline regimen. Among the 58 patients whose baseline regimen contained у2 drugs, 18 patients (31.0%) harbored isolates that were resistant to 2 of these drugs, and among the 55 who started у3 drugs, 7 patients (12.7%) harbored isolates that were resistant to 3 drugs.
Among the 51 patients who started a PI, 23 (45.1%) had strains that were resistant to the PI they started. All 3 patients who started nelfinavir carried strains resistant to that drug (mean IC 50 , 30.3). Patients starting ritonavir were more likely to harbor ritonavir-resistant isolates (5 of 7) than were patients who started indinavir (12 indinavir-resistant strains of 32 patients; x 2 test, ) or saquinavir (4 of 10, Fisher's exact P = .10 test,
). Mean IC 50 s were 42.8 for saquinavir, 11.8 for P = .33 indinavir, and 21.2 for ritonavir. Reduced susceptibility to nevirapine was also common: 8 (88.9%) of 9 patients who started nevirapine harbored strains resistant to nevirapine (mean IC 50 , 988.8).
Among the nucleosides, reduced susceptibility to zidovudine and lamivudine were the most frequent (15 of 21 and 30 of 39, respectively), whereas reduced susceptibility to didanosine was rare (3 of 16 and 8 of 60). None of the 35 patients who started stavudine had isolates resistant to that drug. Likewise, none of the 3 patients who started zalcitabine had zalcitabine-resistant isolates. Overall, 46 (76.7%) of patients' virus strains were resistant to у1 drug in their baseline regimen within 36 weeks after the rebound in virus load. At the time of resistance testing, 5 patients (8.3%) had temporarily discontinued treatment. Since treatment interruptions may alter the HIV susceptibility status, we recalculated the proportion of isolates that were resistant to у1 drug in the baseline regimen after excluding these patients; however, the results were similar (42 [76.4%] of 55). Of those 55 patients, 40 (72.7%) had switched to a different drug combination from the baseline combination by the time of resistance testing (table 2) . For the 55 patients who were still receiving some treatment at the time of the resistance testing, we calculated the proportion of isolates that were resistant to у1 of the drugs they had ever received (or were currently receiving) at the time of the test. Of 53 patients, 47 (88.7%) had resistant strains and 6 patients (11.3%) harbored isolates sus- ceptible to all drugs received. Two patients were excluded from these calculations because of incomplete resistance test results. The main analysis was repeated using the subgroup of patients who had a phenotypic resistance test, a drop in virus load to !500 copies/mL upon initiation of baseline therapy, and a subsequent rebounded to 1500 copies/mL (  , table 2 ). Ren = 33 sults were similar. In total, 27 patients (78.8%) carried strains that were resistant to у1 of the drugs in their baseline regimen. Of 28 patients who started a PI, 11 (39.3%) were resistant to that PI. Of the 5 patients who started nevirapine, all had isolates resistant to this drug. Again, reduced susceptibility to zidovudine (6 of 9) and lamivudine was more common than reduced susceptibility to the other nucleosides. Of 21 patients who received lamivudine, 15 had lamivudine-resistant strains compared with 2 of 9 who received didanosine (x 2 test, ). P = .01 Patients who had the phenotypic assay test ( ) appeared n = 60 to be similar to the rest of the study population ( ) in n = 538 age (mean, 36.9 years vs. 38.8 in patients without a test, t test ), baseline HIV RNA (mean, 5.08 log 10 copies/mL vs. P = .16 4.89 log 10 copies/mL, ), and number of drugs started P = .15 (mean, 2.94 vs. 2.92). However, patients who had the phenotypic assay tended to have lower baseline CD4 cell counts (124 vs. 200 cells/mL, ), higher virus load at the time of viral P = .001 rebound (mean, 4.44 log 10 copies/mL vs. 3.91 log 10 copies/mL, ), and to have been exposed to more drugs (average P = .0002 nucleosides received before baseline, 1.60 vs. 2.55, ) P = .0001 than those not tested for resistance.
Discussion
This study clearly shows that reduced drug susceptibility is common in patients who experience a virologic failure after starting potent combination therapy. Reduced susceptibility to a PI (especially ritonavir and nelfinavir), nevirapine, zidovudine, and lamivudine were the most frequent while, in agreement with previous reports [10] , reduced susceptibility to stavudine or zalcitabine was extremely rare. While we cannot prove on the basis of our findings that the reduced susceptibility causes virologic failure, we found that resistant strains are generally present after the viral rebound. More than three quarters of the patients who had a viral rebound carried strains that were resistant to у1 drug they received at baseline and almost 90% of the patients harbored strains that were resistant to у1 of the drugs with which they had ever been treated. Of note, 6 patients carried HIV isolates that were wild type to all drugs to which they had been assigned. We have shown that drug holidays (of 2-3 months) may alter patients' susceptibility status [11] . However, all 6 patients were receiving some antiretroviral treatment at the time of resistance testing. It is possible that virologic failure in these patients is associated with other factors related to available plasma drug levels (e.g., pharmacokinetics, adherence) or to factors not considered in this analysis. This is supported by several recent studies that showed that virologic failure can occur in the absence of genotypic resistance [3, 12, 13] . However, the possibility of detecting mixed wild type and mutant virus population with phenotypic assays will depend on the ratio of each variant as well as the individual drugs [14] . Therefore, the possibility that resistance was present but not detected cannot be excluded.
Other possible limitations of this study include the lack of an antivirogram test at the exact time of viral rebound. Thus, patients may have harbored wild type strains at the time of rebound and then developed resistance over the following 36 weeks. Also, because of the lack of a phenotypic-resistance test at baseline, some of the observed drug resistance could have been present at baseline. Finally, since the phenotypic assay was performed only on a proportion of the study population, possible bias due to patient selection cannot be excluded. When they began PI or NNRTI therapy, patients with the phenotypic assay had, on average, lower CD4 cell counts than patients who were not tested for resistance. At the time of the viral rebound, patients with the phenotypic assay had significantly higher virus load concentrations than those who were not tested. It appears that patients who experienced a viral rebound or had a more advanced stage of HIV infection at the time they started their first PI-or NNRTI-containing regimen or at the time of viral rebound were more likely to be tested for resistance after the rebound. Thus, it is possible that the prevalence of resistance in this sample could be an overestimate of the true prevalence in our study population. It is also of note that patients tested for resistance have, on average, been heavily exposed to nucleoside drugs prior to the initiation of the baseline regimen so our conclusions may not apply to patients who first start a PI-or an NNRTI-containing regimen while naive or lightly treated.
In conclusion, these data show that in heavily nucleosideexperienced patients who had a viral rebound after starting a PI-or NNRTI-containing regimen, resistance to у1 drug included in the first potent regimen is usually present. This study neither proves that drug resistance causes virologic failure nor enables a conclusion that resistance is associated with virologic failure since the study only included patients who had a viral rebound. However, performing a resistance test in patients who require a switch in therapy may be important. Clinical utility studies of genotypic testing demonstrate its effectiveness and similar ongoing studies are evaluating phenotypic assays [15] . Testing for resistance and cross-resistance will become increasingly important as new drugs in each class become available for multiple combination regimens. Also, we found that 6 patients who had a viral rebound harbored strains that were wild type to all drugs with which they had been treated, suggesting that drug resistance may not be the only factor that leads to virologic failure and that other factors related to available plasma drug levels (e.g., pharmacokinetics and adherence) need to be assessed in future studies.
